TriangleHEALTH PROFESSIONAL · SOURCE READING
Standard or high-dose cytarabine and mitoxantrone
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Refractory or Recurrent AML / Chemotherapy / Intensive salvage chemotherapy
Evidence (standard or high-dose cytarabine and mitoxantrone):
A study of cytarabine and mitoxantrone included 49 patients with relapsed or refractory AML.[7]
Source links and citations
A study of cytarabine and mitoxantrone included 49 patients with relapsed or refractory AML.[7]
Treatment was successful in 50% to 60% of patients who experienced relapse after initially obtaining a CR, with 62.5% of patients with AML in first relapse achieving M1 marrow.[7,8]
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice